Vildagliptin 50 mg + Metformin Hydrochloride 1000 mg

Introduction

VILDIABATE M 1000 is a powerful combination medication that is used in the management of type 2 diabetes mellitus. This formulation combines Metformin (1000mg) SR (Sustained Release) and Vildagliptin (50mg), two essential agents that work synergistically to control blood sugar levels in patients with diabetes. Type 2 diabetes is a chronic condition characterized by elevated blood sugar levels due to the body's inability to properly use insulin or produce sufficient insulin. Managing this condition effectively requires a comprehensive treatment strategy, and VILDIABATE M 1000 serves as an important part of this approach.

In this article, we will explore the key components of VILDIABATE M 1000, including the mechanisms of action, dosage guidelines, side effects, and benefits. Additionally, we will delve into its practical uses, its role in controlling diabetes, and considerations for patients considering this medication.

Key Ingredients of VILDIABATE M 1000

VILDIABATE M 1000 consists of two primary ingredients:

1. Metformin (1000mg) SR
2. Vildagliptin (50mg)

1. Metformin (1000mg) SR

Metformin is an oral antidiabetic medication that belongs to the biguanide class. It works primarily by reducing hepatic glucose production (the amount of sugar the liver produces) and increasing the sensitivity of muscle cells to insulin, thereby enhancing glucose uptake and utilization. Additionally, Metformin helps lower the absorption of glucose from the gastrointestinal tract.

Metformin does not stimulate insulin secretion, and therefore, does not cause hypoglycemia (low blood sugar) in the absence of other medications that increase insulin levels.

The SR (Sustained Release) form of Metformin allows for prolonged and steady release of the drug over time, ensuring stable blood glucose control and reducing side effects, such as gastrointestinal discomfort, commonly associated with regular-release Metformin.

2. Vildagliptin (50mg)

Vildagliptin is a DPP-4 inhibitor (Dipeptidyl Peptidase-4 inhibitor), which works by increasing the levels of incretin hormones, such as GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory peptide). These hormones help regulate insulin secretion by stimulating the pancreas to release insulin in response to meals and reduce glucagon secretion, which prevents the liver from releasing excess glucose.

By inhibiting the DPP-4 enzyme, Vildagliptin prolongs the action of incretin hormones, leading to improved insulin secretion and reduced blood glucose levels after meals.

How VILDIABATE M 1000 Works

VILDIABATE M 1000 works through the synergistic actions of Metformin and Vildagliptin, targeting different mechanisms involved in glucose regulation.

• Metformin primarily reduces the production of glucose by the liver and improves insulin sensitivity, which helps the body use glucose more effectively.
• Vildagliptin enhances insulin secretion and decreases glucose production by inhibiting the DPP-4 enzyme, promoting better postprandial (after meal) glucose control.

Together, these two medications not only control fasting blood glucose levels but also postprandial glucose levels, both of which are crucial for comprehensive diabetes management.

Key Benefits of VILDIABATE M 1000

VILDIABATE M 1000 provides several advantages in managing type 2 diabetes, making it an excellent choice for patients who have not achieved adequate glycemic control with diet and exercise alone. Some of the key benefits include:

1. Effective Blood Sugar Control
   The combination of Metformin and Vildagliptin results in enhanced blood sugar control, reducing both fasting and postprandial glucose levels effectively.

2. Dual Mechanism of Action
   The dual approach of Metformin’s insulin sensitivity improvement and Vildagliptin’s incretin hormone modulation allows for comprehensive control of diabetes, making it more effective than monotherapy in many cases.

3. Lower Risk of Hypoglycemia
   As neither Metformin nor Vildagliptin increases insulin production on its own, the risk of hypoglycemia (low blood sugar) is significantly lower compared to other diabetes medications that increase insulin secretion.

4. Sustained Release Formulation
   The Sustained Release formulation of Metformin in VILDIABATE M 1000 allows for a gradual release of the drug, minimizing gastrointestinal discomfort such as nausea, bloating, and diarrhea, which are common with immediate-release Metformin.

5. Weight Neutrality
   Unlike many other antidiabetic drugs, VILDIABATE M 1000 is typically weight-neutral, meaning it does not promote significant weight gain. This is an important consideration for patients who are overweight or obese, conditions that often accompany type 2 diabetes.

6. Convenient Dosing
   The combination tablet offers a more convenient dosing regimen, requiring fewer daily doses, which can improve patient adherence to treatment.

Dosage and Administration of VILDIABATE M 1000

The typical starting dose of VILDIABATE M 1000 is one tablet once daily, preferably with the evening meal to reduce the risk of gastrointestinal side effects. The maximum recommended dose is one tablet per day. However, dosage may vary based on individual patient requirements and the prescribing physician's recommendations.

If switching from Metformin or Vildagliptin monotherapy, the dosage of VILDIABATE M 1000 should be adjusted accordingly to ensure appropriate blood glucose control. Patients should not take more than one tablet per day, as it exceeds the recommended dose of Metformin (1000mg) SR and Vildagliptin (50mg).

Side Effects of VILDIABATE M 1000

As with any medication, VILDIABATE M 1000 may cause side effects. Most of these are mild and transient, but serious side effects, though rare, can occur. Common side effects include:

1. Gastrointestinal Disturbances
   Metformin can cause gastritis, diarrhea, nausea, and bloating, particularly when starting treatment. The sustained-release formulation helps mitigate these symptoms.

2. Hypoglycemia (Low Blood Sugar)
   While the risk is low compared to other antidiabetic drugs, combining VILDIABATE M 1000 with other medications like insulin or sulfonylureas can increase the risk of hypoglycemia.

3. Lactic Acidosis
   A very rare but serious side effect of Metformin is lactic acidosis, a condition where there is a buildup of lactic acid in the blood. This condition requires immediate medical attention and is more likely to occur in patients with kidney or liver problems.

4. Headache, Dizziness
   Some patients may experience headaches, dizziness, or fatigue during the initial stages of treatment, although these symptoms typically resolve as the body adjusts.

5. Upper Respiratory Infections
   As Vildagliptin works by modulating the immune system, some patients may experience mild respiratory infections, such as a runny nose or sore throat.

6. Skin Reactions
   In rare cases, Vildagliptin may cause skin rashes or itching.

If any of these side effects persist or worsen, it is essential to contact a healthcare professional promptly.

Precautions and Considerations

Before starting VILDIABATE M 1000, patients should inform their doctor about any pre-existing conditions, such as:

• Kidney or liver impairment
• Heart failure
• History of lactic acidosis
• Pregnancy or breastfeeding (VILDIABATE M 1000 is not recommended during pregnancy or breastfeeding unless absolutely necessary)

Patients should also avoid alcohol consumption while taking this medication, as it increases the risk of lactic acidosis and may interfere with the effectiveness of the medication.

Conclusion

VILDIABATE M 1000 is an effective and convenient option for managing type 2 diabetes. The combination of Metformin (1000mg) SR and Vildagliptin (50mg) works through complementary mechanisms to achieve better glucose control, reduce the risk of hypoglycemia, and help patients maintain a healthy weight. While side effects are generally mild, proper monitoring and adherence to prescribed dosages are important for achieving optimal results.

Patients taking VILDIABATE M 1000 should work closely with their healthcare providers to monitor blood glucose levels and make necessary adjustments to their treatment plan. This will ensure a holistic approach to managing type 2 diabetes, allowing patients to lead healthier and more active lives.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW